Krämer I - Search Results

1

Drug safety in thyroid eye disease - a systematic review.

Wolf J, Mitka KI, Hubalewska-Dydejczyk A, Krämer I, Kahaly GJ. Wolf J, et al. Among authors: kramer i. Expert Opin Drug Saf. 2022 Jul;21(7):881-912. doi: 10.1080/14740338.2022.2069239. Epub 2022 Aug 15. Expert Opin Drug Saf. 2022. PMID: 35447047

2

Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.

Riedl M, Kolbe E, Kampmann E, Krämer I, Kahaly GJ. Riedl M, et al. Among authors: kramer i. J Endocrinol Invest. 2015 Feb;38(2):177-82. doi: 10.1007/s40618-014-0227-x. Epub 2015 Jan 10. J Endocrinol Invest. 2015. PMID: 25576458

3

Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy.

Riedl M, Kuhn A, Krämer I, Kolbe E, Kahaly GJ. Riedl M, et al. Among authors: kramer i. J Endocrinol Invest. 2016 Jun;39(6):687-94. doi: 10.1007/s40618-016-0441-9. Epub 2016 Feb 17. J Endocrinol Invest. 2016. PMID: 26886940

4

Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application.

Längericht J, Krämer I, Kahaly GJ. Längericht J, et al. Among authors: kramer i. Ther Adv Endocrinol Metab. 2020 Dec 14;11:2042018820958335. doi: 10.1177/2042018820958335. eCollection 2020. Ther Adv Endocrinol Metab. 2020. PMID: 33403097 Free PMC article. Review.

5

A Novel Monoclonal Antibody Degrades the Thyrotropin Receptor Autoantibodies in Graves' Disease.

Wolf J, Alt S, Krämer I, Kahaly GJ. Wolf J, et al. Among authors: kramer i. Endocr Pract. 2023 Jul;29(7):553-559. doi: 10.1016/j.eprac.2023.04.002. Epub 2023 Apr 18. Endocr Pract. 2023. PMID: 37080298 Free article. Clinical Trial.

6

[Bevacizumab. Progress in cancer therapy by antiangiogenesis].

Krämer I, Lipp HP. Krämer I, et al. Med Monatsschr Pharm. 2006 Jul;29(7):249-54; quiz 255-6. Med Monatsschr Pharm. 2006. PMID: 16866078 Review. German.

7

Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.

Krämer I, Lipp HP. Krämer I, et al. J Clin Pharm Ther. 2007 Feb;32(1):1-14. doi: 10.1111/j.1365-2710.2007.00800.x. J Clin Pharm Ther. 2007. PMID: 17286784 Review.

8

Increased medication compliance of liver transplant patients switched from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen.

Eberlin M, Otto G, Krämer I. Eberlin M, et al. Among authors: kramer i. Transplant Proc. 2013 Jul-Aug;45(6):2314-20. doi: 10.1016/j.transproceed.2012.10.037. Epub 2013 May 29. Transplant Proc. 2013. PMID: 23726723

9

Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors.

Rosentreter J, Alt J, Fried M, Chakupurakal G, Stratmann J, Krämer I. Rosentreter J, et al. Among authors: kramer i. J Oncol Pharm Pract. 2021 Jul;27(5):1147-1158. doi: 10.1177/1078155220946381. Epub 2020 Aug 3. J Oncol Pharm Pract. 2021. PMID: 32746691

10

Inhalation solutions--which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers--update 2013.

Kamin W, Erdnüss F, Krämer I. Kamin W, et al. Among authors: kramer i. J Cyst Fibros. 2014 May;13(3):243-50. doi: 10.1016/j.jcf.2013.09.006. Epub 2013 Oct 28. J Cyst Fibros. 2014. PMID: 24172851 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

392 results

Search Page

Filters